Search results for "OUTCOME"

showing 10 items of 5148 documents

Evidence that the endometrial microbiota has an effect on implantation success or failure

2016

Background Bacterial cells in the human body account for 1–3% of total body weight and are at least equal in number to human cells. Recent research has focused on understanding how the different bacterial communities in the body (eg, gut, respiratory, skin, and vaginal microbiomes) predispose to health and disease. The microbiota of the reproductive tract has been inferred from the vaginal bacterial communities, and the uterus has been classically considered a sterile cavity. However, while the vaginal microbiota has been investigated in depth, there is a paucity of consistent data regarding the existence of an endometrial microbiota and its possible impact in reproductive function. Objecti…

0301 basic medicinePregnancy RatePrevotellaUterusPhysiologyPilot ProjectsEndometriumPolymerase Chain ReactionEndometrium0302 clinical medicinePregnancyRNA Ribosomal 16SLactobacillusProspective Studiesmedia_commonPrincipal Component Analysis030219 obstetrics & reproductive medicineMicrobiotaObstetrics and GynecologyGeneral MedicineGardnerella vaginalisBacterial Typing TechniquesTreatment Outcomemedicine.anatomical_structureVaginaVaginaFemaleLive birthLive Birthmedicine.medical_specialtymedia_common.quotation_subjectFertilization in VitroBiology03 medical and health sciencesmedicineHumansEmbryo ImplantationMicrobiomeMenstrual CycleMenstrual cycleGynecologyPregnancySequence Analysis RNAbusiness.industryLuteinizing HormoneEmbryo Transfermedicine.diseasebiology.organism_classificationLactobacillusLogistic Models030104 developmental biologySpainCase-Control StudiesInfertilityMultivariate AnalysisbusinessGenome BacterialAmerican Journal of Obstetrics and Gynecology
researchProduct

KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting

2020

In advanced stage non-small cell lung cancer (NSCLC) patients, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) testing may soon acquire a predictive significance to select patients for AMG510 treatment. Since tissue samples are not always available, liquid biopsy may represent a viable option for KRAS testing. Here, we review the last three years clinical practice performed on 194 plasma based liquid biopsies by next generation sequencing (NGS) SiRe(®) panel. In particular, 36 (18.6%) KRAS mutated cases were identified, with an overall median allelic frequency of 5.0% (ranging between 0.2% and 46.8%). No concomitant mutations were observed in the other NSCLC clinical relevant genes includ…

0301 basic medicinePulmonary and Respiratory MedicineAMG510Settore MED/06 - Oncologia MedicaViral Oncogenemedicine.disease_cause03 medical and health sciencesBasal (phylogenetics)0302 clinical medicineG12CMedicineEpidermal growth factor receptorLiquid biopsyLung cancerneoplasmsMutationbiologyLiquid biopsybusiness.industryKirsten Rat Sarcoma Viral Oncogene Homolog (KRAS)Review Article on Improving Outcomes in Lung Cancer Through Early Diagnosis and Smoking Cessationmedicine.diseaseBasal setting030104 developmental biologyNext generation sequencing (NGS)030220 oncology & carcinogenesisCancer researchbiology.proteinBiomarker (medicine)KRASLung cancerbusiness
researchProduct

Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional Study.

2019

The objective was to assess quality of life (QoL) in lung cancer survivors, compare it to the general population, and identify factors associated with global QoL, physical functioning, emotional functioning, fatigue, pain, and dyspnea.Data from NSCLC patients who had survived 1 year or longer after diagnosis were collected cross-sectionally in a multicenter study. QoL was assessed with the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 and the lung cancer module QLQ-LC13 across different clinical subgroups and compared to age- and sex-standardized general population reference values. Multivariable linear regression analyses wer…

0301 basic medicinePulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyLung NeoplasmsCross-sectional studyPopulation03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineCarcinoma Non-Small-Cell LungSurveys and QuestionnairesMedicineHumansSurvivorsLung cancereducationAgedAged 80 and overeducation.field_of_studybusiness.industryCancerMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyhumanitiesSurvival Rate030104 developmental biologyCross-Sectional StudiesOncologyMulticenter study030220 oncology & carcinogenesisQuality of LifePatient-reported outcomeFemaleActive treatmentbusinessFollow-Up StudiesJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
researchProduct

Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysi…

2020

Abstract Objectives To evaluate the effectiveness and safety of nintedanib plus docetaxel in patients with advanced adenocarcinoma non-small cell lung cancer (NSCLC) previously treated with both chemo- and immunotherapy. Materials and methods LUME-BioNIS is a European, prospective, multicenter, non-interventional study of patients with advanced adenocarcinoma NSCLC, who initiated nintedanib plus docetaxel after first-line chemotherapy in routine practice according to the approved nintedanib EU label. The primary objective is to explore whether molecular biomarkers can predict overall survival (OS). Information on clinical or radiologic progression and death, and adverse drug reactions (ADRs…

0301 basic medicinePulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtyIndolesLung Neoplasmsmedicine.medical_treatmentSubgroup analysisPembrolizumabDocetaxelAdenocarcinoma03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAtezolizumabInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesLung cancerChemotherapybusiness.industrymedicine.disease030104 developmental biologyTreatment OutcomeOncologychemistryDocetaxel030220 oncology & carcinogenesisNintedanibTaxoidsImmunotherapyNivolumabbusinessmedicine.drugLung cancer (Amsterdam, Netherlands)
researchProduct

The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future?

2016

Exclusive chemoradiotherapy (CRT) delivering 50 Gy over 5 weeks with cisplatin and fluorouracil-based chemotherapy is a cornerstone in locally advanced esophageal cancer or non-operable patients since the results of the pivotal study of US Intergroup RTOG-8501 (1). This trial has successfully demonstrated that some patients with esophageal carcinoma may be long-term survivors so that this treatment is now definitely accepted as curative (2). Nevertheless the prognosis is still very disappointing with a 5-year overall survival rate of approximately 25%. Attempts to improve overall survival by escalating the dose of radiotherapy with concurrent cisplatin and fluorouracil has been assessed in …

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtymedicine.medical_treatmentLocally advancedCetuximab[SDV.CAN]Life Sciences [q-bio]/CancerOutcomes[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract[ SDV.CAN ] Life Sciences [q-bio]/CancerIntensity-Modulated Radiotherapy03 medical and health sciences0302 clinical medicineInternal medicineCarcinomaMedicineComputingMilieux_MISCELLANEOUSCapecitabineCisplatinChemotherapybusiness.industryCarcinomaInduction ChemotherapyEsophageal cancermedicine.diseaseRadiation-Therapy3. Good healthRadiation therapyEditorial030104 developmental biologyChemoradiationFluorouracil030220 oncology & carcinogenesisIi Randomized-TrialCisplatinbusiness[ SDV.MHEP.PSR ] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractChemoradiotherapymedicine.drug
researchProduct

Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell l…

2019

Abstract Objectives To evaluate the effect on quality of life (QOL) of the addition of cisplatin to single-agent chemotherapy in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC) enrolled in two parallel phase 3 trials, MILES-3 and MILES-4. Patients and methods Advanced NSCLC pts, >70 years old, performance status (PS) 0–1, were eligible. Patients were randomly assigned to chemotherapy without or with cisplatin. EORTC QLQ C30 and LC13 questionnaires were planned at baseline, end of cycle 1 and end of cycle 2 in both trials and were used for joint QOL analysis. Trial-specific data including questionnaires at non-shared time-points were used for additional ana…

0301 basic medicinePulmonary and Respiratory MedicineQuality of lifeMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsNauseamedicine.medical_treatmentRandomizedNSCLCPhase 303 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineSurveys and QuestionnairesCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSurveys and QuestionnaireLung cancerAgedNeoplasm StagingCisplatinAged 80 and overChemotherapyAntineoplastic Combined Chemotherapy ProtocolPerformance statusbusiness.industryAlopeciamedicine.diseaseDysphagiaLung Neoplasm030104 developmental biologyTreatment OutcomeOncology030220 oncology & carcinogenesisVomitingStomatitis AphthousFemalemedicine.symptomCisplatinbusinessElderly patientStomatitis Aphthoumedicine.drugHuman
researchProduct

Outcome of liver transplantation for hepatopulmonary syndrome: a Eurotransplant experience.

2019

Hepatopulmonary syndrome (HPS) is a pulmonary vascular complication of liver disease that affects up to 30% of patients with cirrhosis [1]. Intrapulmonary vascular dilatations and shunts result in gas exchange abnormalities, ranging from elevated alveolar-arterial oxygen gradients with no hypoxemia to very severe hypoxemia [1, 2]. Currently, liver transplantation (LT) is the only treatment option [3]. The Model for End-Stage Liver Disease (MELD) is a scoring system for assessing liver disease severity that has been validated to predict the 3-months waitlist mortality, and is used by Eurotransplant for prioritising allocation of liver transplants [4]. Footnotes This manuscript has recently b…

0301 basic medicinePulmonary and Respiratory MedicineRiskScoring systemmedicine.medical_treatmentMedizinVascular complicationLiver transplantationEnd Stage Liver Disease03 medical and health sciences0302 clinical medicineSevere hypoxemiaNothingMedicineHumansRegistriesProportional Hazards ModelsRetrospective Studiesbusiness.industryConflict of interestTreatment optionsLiver TransplantationEuropeOxygen030104 developmental biologyTreatment OutcomeLaw030211 gastroenterology & hepatologybusinessProduction teamHepatopulmonary SyndromeThe European respiratory journal
researchProduct

Linezolid and atorvastatin impact on pneumonia caused by Staphyloccocus aureus in rabbits with or without mechanical ventilation

2017

International audience; Pneumonia may involve methicillin-resistant Staphylococcus aureus (MRSA), with elevated rates of antibiotics failure. The present study aimed to assess the effect of statins given prior to pneumonia development. Spontaneously breathing (SB) or mechanically ventilated (MV) rabbits with pneumonia received atorvastatin alone, linezolid (LNZ) alone, or a combination of both (n = 5 in each group). Spontaneously breathing and MV untreated infected animals (n = 11 in each group), as well as uninfected animals (n = 5 in each group) were used as controls. Microbiological features and inflammation were evaluated. Data are presented as medians (interquartile range). Linezolid a…

0301 basic medicinePulmonologyPhysiologymedicine.medical_treatmentAtorvastatinStaphylococcuslcsh:MedicineInduced Lung Injurychemistry.chemical_compound0302 clinical medicineImmune PhysiologyMedicine and Health SciencesAtorvastatinlcsh:ScienceImmune ResponseLungPathology and laboratory medicineMammalsInnate Immune SystemMultidisciplinaryRespirationDrugsEukaryotaAnimal ModelsMedical microbiology3. Good healthBody FluidsUp-Regulationmedicine.anatomical_structureBloodExperimental Organism SystemsBreathingAnesthesiaVertebratesLeporidsCytokinesMethicillin-resistant Staphylococcus aureusRabbitsPathogensAnatomyIn-Vivomedicine.drugResearch Article[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]Staphylococcus aureusStatinmedicine.drug_class030106 microbiologyImmunologyOutcomesResearch and Analysis MethodsMicrobiologySepsis03 medical and health sciencesSigns and SymptomsDiagnostic MedicineSepsismedicinePneumonia BacterialAnimalsTidal-VolumeMortality[ SDV.OT ] Life Sciences [q-bio]/Other [q-bio.OT]Mechanical ventilationPharmacologyInflammationLungBacteriabusiness.industrylcsh:ROrganismsLinezolidStatinsBiology and Life Sciences030208 emergency & critical care medicinePneumoniaMolecular Developmentmedicine.diseaseRespiration ArtificialToll-Like Receptor 2Microbial pathogensPneumoniachemistryBacteremiaImmune SystemLinezolidAmnioteslcsh:QBacterial pathogensbusinessPhysiological ProcessesDevelopmental BiologyModel
researchProduct

Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublis…

2018

Zofenopril is a lipophilic, sulfhydryl group-containing angiotensin-converting enzyme (ACE)-inhibitor, characterized by wide tissue distribution, long duration of action, and pleiotropic effects on endothelial dysfunction. Its clinical efficacy and safety have been described in the four randomized controlled trials of the SMILE program, which globally enrolled more than 3600 patients in post-acute myocardial infarction (AMI) setting. The SMILE-4 study specifically selected patients with left ventricular dysfunction at admission, and compared the effects of zofenopril or ramipril in combination with acetylsalicylic acid (ASA). Zofenopril demonstrated its superiority over ramipril in reducing…

0301 basic medicineRamiprilmedicine.medical_specialtyCaptoprilPopulationMyocardial InfarctionCardiologyAngiotensin-Converting Enzyme InhibitorsHeart failureReviewAcute myocardial infarction030204 cardiovascular system & hematologylaw.inventionZofenopril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialDouble-Blind MethodRamiprillawInternal medicineAcute myocardial infarction; Angiotensin-converting enzyme inhibitors; Cardiology; Heart failure; Left ventricular dysfunction; Ramipril; Zofenopril; Pharmacology (medical)MedicineHumansPharmacology (medical)Myocardial infarctioneducationRandomized Controlled Trials as Topiceducation.field_of_studyLeft ventricular dysfunctionEjection fractionbusiness.industryGeneral Medicinemedicine.diseaseZofenopril030104 developmental biologyTreatment OutcomechemistryAngiotensin-converting enzyme inhibitorHeart failureCardiologyNumber needed to treatbusinessmedicine.drug
researchProduct

Performance and risk in the Brazilian banking industry

2021

Andres J. Picazo-Tadeo aknowledges the financial support from the Generalitat Valenciana (project PROMETEO 2018/102).

0301 basic medicineRiskPerformanceCommercial and investment banksSample (statistics)Outcome (game theory)Investment banking03 medical and health sciences0302 clinical medicineData envelopment analysisProduction (economics)lcsh:Social sciences (General)lcsh:Science (General)Directional distance functionsIndustrial organizationMultidisciplinarybusiness.industryBrazilian banking industryBanking industryTechnical performance030104 developmental biologyData Envelopment AnalysisDirectional distance functionlcsh:H1-99business030217 neurology & neurosurgeryResearch Articlelcsh:Q1-390Heliyon
researchProduct